204 related articles for article (PubMed ID: 34362355)
1. Carbon ion radiotherapy for prostate cancer with bladder invasion.
Miyasaka Y; Kawamura H; Sato H; Kubo N; Mizukami T; Matsui H; Miyazawa Y; Ito K; Nakano T; Suzuki K; Ohno T
BMC Urol; 2021 Aug; 21(1):106. PubMed ID: 34362355
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II trial of definitive carbon ion radiotherapy for prostate cancer: evaluation of shortening of treatment period to 3 weeks.
Nomiya T; Tsuji H; Maruyama K; Toyama S; Suzuki H; Akakura K; Shimazaki J; Nemoto K; Kamada T; Tsujii H;
Br J Cancer; 2014 May; 110(10):2389-95. PubMed ID: 24722181
[TBL] [Abstract][Full Text] [Related]
3. Significant impact of biochemical recurrence on overall mortality in patients with high-risk prostate cancer after carbon-ion radiotherapy combined with androgen deprivation therapy.
Kasuya G; Ishikawa H; Tsuji H; Nomiya T; Makishima H; Kamada T; Akakura K; Suzuki H; Shimazaki J; Haruyama Y; Kobashi G; Tsujii H;
Cancer; 2016 Oct; 122(20):3225-3231. PubMed ID: 27351298
[TBL] [Abstract][Full Text] [Related]
4. Preliminary result of carbon-ion radiotherapy using the spot scanning method for prostate cancer.
Takakusagi Y; Katoh H; Kano K; Anno W; Tsuchida K; Mizoguchi N; Serizawa I; Yoshida D; Kamada T
Radiat Oncol; 2020 May; 15(1):127. PubMed ID: 32460889
[TBL] [Abstract][Full Text] [Related]
5. Long-term clinical outcomes after 12-fractionated carbon-ion radiotherapy for localized prostate cancer.
Sato H; Kasuya G; Ishikawa H; Nomoto A; Ono T; Nakajima M; Isozaki Y; Yamamoto N; Iwai Y; Nemoto K; Ichikawa T; Tsuji H;
Cancer Sci; 2021 Sep; 112(9):3598-3606. PubMed ID: 34107139
[TBL] [Abstract][Full Text] [Related]
6. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma.
Kong L; Gao J; Hu J; Hu W; Guan X; Lu R; Lu JJ
Chin J Cancer; 2016 Dec; 35(1):101. PubMed ID: 28007028
[TBL] [Abstract][Full Text] [Related]
8. Cancer-specific mortality of high-risk prostate cancer after carbon-ion radiotherapy plus long-term androgen deprivation therapy.
Kasuya G; Ishikawa H; Tsuji H; Haruyama Y; Kobashi G; Ebner DK; Akakura K; Suzuki H; Ichikawa T; Shimazaki J; Makishima H; Nomiya T; Kamada T; Tsujii H;
Cancer Sci; 2017 Dec; 108(12):2422-2429. PubMed ID: 28921785
[TBL] [Abstract][Full Text] [Related]
9. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer.
Jereczek-Fossa BA; Beltramo G; Fariselli L; Fodor C; Santoro L; Vavassori A; Zerini D; Gherardi F; Ascione C; Bossi-Zanetti I; Mauro R; Bregantin A; Bianchi LC; De Cobelli O; Orecchia R
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):889-97. PubMed ID: 21277113
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen dynamics after neoadjuvant androgen-deprivation therapy and carbon ion radiotherapy for prostate cancer.
Takakusagi Y; Oike T; Kano K; Anno W; Tsuchida K; Mizoguchi N; Serizawa I; Yoshida D; Katoh H; Kamada T
PLoS One; 2020; 15(11):e0241636. PubMed ID: 33156884
[TBL] [Abstract][Full Text] [Related]
11. Conversion and validation of rectal constraints for prostate carcinoma receiving hypofractionated carbon-ion radiotherapy with a local effect model.
Wang W; Li P; Sheng Y; Huang Z; Zhao J; Hong Z; Shahnazi K; Jiang GL; Zhang Q
Radiat Oncol; 2021 Apr; 16(1):72. PubMed ID: 33849589
[TBL] [Abstract][Full Text] [Related]
12. The role of carbon ion radiotherapy for unresectable locally recurrent rectal cancer: a single institutional experience.
Cai X; Du Y; Wang Z; Li P; Yu Z; Zhang Q; Zhang Z
Radiat Oncol; 2020 Aug; 15(1):209. PubMed ID: 32859234
[TBL] [Abstract][Full Text] [Related]
13. Prognostic analysis of radiation pneumonitis: carbon-ion radiotherapy in patients with locally advanced lung cancer.
Hayashi K; Yamamoto N; Karube M; Nakajima M; Matsufuji N; Tsuji H; Ogawa K; Kamada T
Radiat Oncol; 2017 May; 12(1):91. PubMed ID: 28558766
[TBL] [Abstract][Full Text] [Related]
14. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
Baumann BC; Baumann JC; Christodouleas JP; Soffen E
Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
[TBL] [Abstract][Full Text] [Related]
15. Carbon ion radiotherapy for mesonephric adenocarcinoma of the uterine cervix: a case report.
Kobayashi N; Oike T; Ando K; Murata K; Tamaki T; Noda SE; Kogure K; Nobusawa S; Oyama T; Ohno T
J Med Case Rep; 2024 May; 18(1):228. PubMed ID: 38720351
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer.
Mizowaki T; Norihisa Y; Takayama K; Ikeda I; Inokuchi H; Nakamura K; Kamba T; Inoue T; Kamoto T; Ogawa O; Hiraoka M
Int J Clin Oncol; 2016 Feb; 21(1):148-55. PubMed ID: 26141133
[TBL] [Abstract][Full Text] [Related]
17. Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation.
Aizawa R; Takayama K; Nakamura K; Inoue T; Yamasaki T; Kobayashi T; Akamatsu S; Ogawa O; Mizowaki T
Int J Clin Oncol; 2019 Oct; 24(10):1247-1255. PubMed ID: 31152322
[TBL] [Abstract][Full Text] [Related]
18. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
19. Safety of Carbon-ion Radiotherapy for Prostate Cancer After Rectal Cancer Surgery.
Takakusagi Y; Koge H; Kano K; Shima S; Tsuchida K; Mizoguchi N; Yoshida D; Kamada T; Katoh H
Anticancer Res; 2023 Jun; 43(6):2691-2695. PubMed ID: 37247892
[TBL] [Abstract][Full Text] [Related]
20. Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: Association between dose and late toxicity.
Rose JN; Crook JM; Pickles T; Keyes M; Morris WJ
Brachytherapy; 2015; 14(3):342-9. PubMed ID: 25727178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
